US FDA Warns Torrent Over Losartan Process Validation, OOS Invalidation Failures

 
• By Bowman Cox

Warning letter stemming from global nitrosamine investigation raises new concerns about Indian manufacturer.

Vintage inscription made by old typewriter, warning
Letter is another sign of the increased scrutiny the valsartan crisis has brought to pharmaceutical manufacturers.

More from Manufacturing

More from Compliance